Saturday 17 October 2026 Export PDSB’s income statement to Excel — free account

PDS Biotechnology Corporation

In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 69.3% and total debt fell 66.6%, each against the same quarter a year earlier.

1.12 0.18 −13.85%

Follow PDSB

Alert me

Market cap: $72.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.19%

Capital & Financial Ratios $m

Market Cap 72.76

Revenue —

Net Income (33.67)

Free Cash Flow (16.78)

Net Debt (1.26)

Current Ratio 0.57

Debt/Equity (1.21)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 37.16%

Next Y EPS Growth 35.48%

Next Y revenue growth —

Next 5Y EPS Growth 32.26%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	57	42	27	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	59	45	28	7

	2023	2024	2025	Q'26
Payables	7	2	4	6
ST’ Debt	—	—	—	4
Other	—	—	—	—
	14	17	9	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(22.76%)	(19.36%)	(40.54%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(9)	(9)	(6)	(4)	(28)
’24	(10)	(9)	(8)	(8)	(35)
’23	(13)	(5)	(7)	(8)	(34)
’22	(6)	(6)	(6)	(8)	(26)
’21	(4)	1	(5)	(5)	(12)
’20	(3)	(4)	(1)	(5)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(9)	(9)	(6)	(4)	(28)
’24	(10)	(9)	(8)	(8)	(35)
’23	(13)	(5)	(7)	(8)	(34)
’22	(6)	(6)	(6)	(8)	(26)
’21	(4)	1	(5)	(5)	(12)
’20	(3)	(4)	(1)	(5)	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.18)	—	—	—
’25	(0.21)	(0.21)	(0.19)	(0.14)	(0.74)
’24	(0.30)	(0.23)	(0.29)	(0.21)	(1.03)
’23	(0.32)	(0.37)	(0.35)	(0.34)	(1.39)
’22	(0.32)	(0.20)	(0.26)	(0.67)	(1.43)
’21	(0.14)	(0.03)	(0.24)	(0.23)	(0.66)
’20	(0.39)	(0.19)	(0.23)	(0.16)	(0.89)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	124.64	146.02	5.60	2.02	0.62	2.13	2.89	3.80	1.53	0.70	Analyst estimates 2026–2028 Powerpack
	High	277.20	268.00	355.40	11.80	4.98	17.85	13.65	12.50	6.68	2.20
People
People	Employees	31	38	10	15	15	22	26	25	24	21
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(41)	(53)	(4)	(7)	(15)	(21)	(42)	(44)	(38)	(36)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(39)	(51)	(4)	(7)	(15)	(17)	(41)	(43)	(38)	(34)
	Depreciation	0	0	0	0	0	0	0	1	1	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(26.80)	(33.40)	(1.15)	(1.44)	(0.89)	(0.66)	(1.43)	(1.39)	(1.03)	(0.74)
	Cash flow	(22.30)	(26.78)	(0.47)	(3.71)	(0.79)	(0.49)	(0.90)	(1.09)	(0.96)	(0.60)
	Capex	(0.48)	(0.12)	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(22.78)	(26.90)	(0.47)	(3.66)	(0.79)	(0.49)	(0.90)	(1.09)	(0.96)	(0.60)
	Book value	61.86	41.04	(0.62)	2.40	1.62	2.47	1.54	0.84	0.52	0.20
	Shares, m	1	2	3	5	17	26	29	31	36	46
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(32)	(41)	(2)	(18)	(13)	(12)	(26)	(34)	(35)	(28)
	Capex	(1)	0	—	0	—	—	—	—	0	—
	Free cash flow	(33)	(41)	(2)	(18)	(13)	(12)	(26)	(34)	(35)	(28)
Balance, $m
Balance, $m	Working capital	101	76	(2)	12	27	63	67	45	28	19
	Total debt	15	20	0	—	0	0	23	20	9	12
	Net debt	(91)	(68)	0	(12)	(28)	(65)	(51)	(37)	(32)	(15)
	Shareholders’ equity	89	62	(2)	12	27	63	44	26	19	9
Returns, %
Returns, %	ROA	(31.69)	(49.98)	(8.27)	(95.51)	(65.43)	(34.50)	(56.66)	(62.97)	(71.81)	(90.95)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(36.67)	(67.08)	(12.72)	(145.33)	(76.48)	(37.46)	(76.21)	(122.46)	(166.65)	(244.16)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
CRDF Cardiff Oncology, Inc.	$75.5M	— (loss-making)	— (loss-making)	−14.05% (below 0%: shrinking)	n/m	−41.36% (below 0%: shrinking)	100.00%	(9,245.19%)	Compare
ACRV Acrivon Therapeutics, Inc.	$75.4M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$75.1M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—	Compare
PDSB PDS Biotechnology Corporation	$72.8M	— (loss-making)	—	—	n/m	+69.32% (above 0%: growing)	0.00%	0.00%
HRTX Heron Therapeutics, Inc.	$71.5M	— (loss-making)	— (loss-making)	+1.25% (above 0%: growing)	n/m	+78.75% (above 0%: growing)	69.28%	(5.43%)	Compare
MNOV MediciNova, Inc.	$71.4M	— (loss-making)	— (loss-making)	+240.56% (above 0%: growing)	n/m	+16.75% (above 0%: growing)	69.33%	(554.36%)	Compare
CGTX Cognition Therapeutics, Inc.	$69.7M	— (loss-making)	—	—	n/m	+45.35% (above 0%: growing)	0.00%	0.00%	Compare
MAIA MAIA Biotechnology, Inc.	$69.2M	— (loss-making)	—	—	n/m	−63.23% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$73.3M	—	—	−6.40%	—	+27.07%	41.58%	(5.43%)

All 614 Biotechnology stocks →